Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Genedrive has Hepatitis C test performance data published in leading medical journal

The paper concluded that Genedrive’s HCV ID Kit was a rapid, simple, portable and accurate near patient molecular test for HCV
Blood samples
The test was validated in a real clinical setting in a resource-limited country

Genedrive PLC (LON:GDR) said analytical performance and field studies of its Hepatitis C (HCV) ID Kit have been published in BMJ Gut, a leading international journal in gastroenterology and hepatology.

The AIM-listed diagnostics company said the publication reports on assay performance data generated and used for its CE-IVD certification, including analytical performance data as well as field performance evaluation.

READ: Genedrive to premiere Hepatitis C test at Asia-Pacific medical exhibition

The paper had concluded that Genedrive’s HCV ID Kit was a rapid, simple, portable and accurate near patient molecular test for HCV, with sensitivity and specificity that fulfils the recent World Health Organization (WHO) target product profile for HCV decentralised testing in low income and middle-income countries.

The group added that pan-genotype performance, with excellent exclusivity for non-HCV pathogens and sensitivity of greater than 98% and specificity of 100% in samples of European and African origin (including South Africa, Kenya, Ghana, Nigeria, Uganda), was observed and that the test was validated in a real clinical setting in a resource-limited country.

David Budd, Genedrive chief executive, commented: "This high impact peer reviewed publication provides further validation of the performance of our Genedrive HCV ID assay.

He added: “We are first to market with a decentralised qualitative molecular HCV test for use at point of need and believe we have the potential to positively impact the continuum of care from screening to cure by supporting real-time treatment decisions."

Genedrive shares were steady in mid-morning trading Tuesday at 38.5p.

--Adds share price--

View full GDR profile View Profile

Genedrive PLC Timeline

Related Articles

Picture of evolis products
April 04 2018
Fillerina® is complementary to the company’s evolis® haircare range.
1530537220_Blood-Test.jpg
July 02 2018
The research and diagnostic company develops cancer-detecting blood tests
leg bones
March 31 2018
"We are now in the position of really trying to kick on in 2018"

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use